Abstract
As the nation implements SARS-CoV-2 vaccination in adults at an unprecedented scale, it is now essential to focus on the prospect of SARS-CoV-2 vaccinations in pediatric populations. To date, no children younger than 12 years have been enrolled in clinical trials. Key challenges and knowledge gaps that must be addressed include (1) rationale for vaccines in children, (2) possible effects of immune maturation during childhood, (3) ethical concerns, (4) unique needs of children with developmental disorders and chronic conditions, (5) health inequities, and (6) vaccine hesitancy. Because COVID-19 is minimally symptomatic in the vast majority of children, a higher acceptable risk threshold is required when evaluating pediatric clinical trials. Profound differences in innate and adaptive immunity during childhood and adolescence are known to affect vaccine responsiveness for a variety of childhood diseases. COVID-19 and the accompanying social disruption, such as the school shutdowns, has been disproportionately damaging to minority and low-income children. In this commentary, we briefly address each of these key issues, specify research gaps, and suggest a broader learning health system approach to accelerate testing and clinical trial development for an ethical and effective strategy to implement a pediatric SARS-CoV-2 vaccine as rapidly and safely as possible.
Impact
-
As the US begins an unprecedented implementation of SARS-CoV-2 vaccination, substantial knowledge gaps have yet to be addressed regarding vaccinations in the pediatric population.
-
Maturational changes in the immune system during childhood have influenced the effectiveness of pediatric vaccines for other diseases and conditions, and could affect SARS-CoV-2 vaccine responsiveness in children.
-
Given that COVID-19 disease is far milder in the majority of children than in adults, the risk–benefit of a pediatric SARS-CoV-2 vaccine must be carefully weighed.
-
The needs of children with developmental disabilities and with chronic disease must be addressed.
-
Minority and low-income children have been disproportionately adversely affected by the COVID-19 pandemic; care must be taken to address issues of health equity regarding pediatric SARS-CoV-2 vaccine trials and allocation.
-
Research and strategies to address general vaccine hesitancy in communities must be addressed in the context of pediatric SARS-CoV-2 vaccines.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
AAP: Include children in COVID-19 vaccine trials (American Academy of Pediatrics, 2020); https://www.aappublications.org/news/2020/11/17/covidvaccinetrials111720.
Leeb, R. T. et al. MMWR, COVID-19 trends among school-aged children—United States, 1 March–19 September 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6939e2.htm.
Opel, D. J., Diekema, D. S. & Ross L. F. Should we mandate a COVID-19 vaccine for children? JAMA Pediatr. 175, 125–126 (2021).
American Academy of Pediatrics. Children and COVID-19: State-level data report (accessed 15 Jan 2021); https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.
Song, X. et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw. Open 3, e2020495 (2020).
Flannery, B. et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. Pediatrics 139, 2010–2014 (2017).
Levin, Z., Choyke, K., Georgiou, A., Sen, S. & Karaca-Mandic, P. Trends in pediatric hospitalizations for coronavirus disease 2019. JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2020.5535 (2021).
Munro, A. P. S. & Faust, S. N. Children are not COVID-19 super spreaders: time to go back to school. Arch. Dis. Child. 105, 618–619 (2020).
Laxminarayan, R. et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science 370, 691–697 (2020).
Blaisdell, L. L., Cohn, W., Pavell, J. R., Rubin, D. S. & Vergales, J. E. Preventing and mitigating SARS-CoV-2 transmission—four overnight camps, Maine, June–August 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1216–20 (2020).
Dorn, E., Hancock, B., Sarakatsannis, J. & Viruleg, E. COVID-19 and Student Learning in the United States: The Hurt Could Last a Lifetime. McKinsey & Company (2020).
Bramer, C. A. et al. Decline in child vaccination coverage during the COVID-19 pandemic—Michigan Care Improvement Registry, May 2016–May 2020. Am. J. Transplant. 20, 1930–1931 (2020).
The Impact of Coronavirus on Food Insecurity. Feeding America (2020); https://www.feedingamerica.org/research/coronavirus-hunger-research.
Dunton, G. F., Do, B. & Wang, S. D. Early effects of the COVID-19 pandemic on physical activity and sedentary behavior in children living in the U.S. BMC Public Health. 20, 1351 (2020).
Loades, M. E. et al. Rapid systematic review: the impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. J. Am. Acad. Child Adolesc. Psychiatry 59, 1218–1239.e3 (2020).
Dooley, D. G., Bandealy, A. & Tschudy, M. M. Low-income children and coronavirus disease 2019 (COVID-19) in the US. JAMA Pediatr. 174, 924–925 (2020).
World Health Organization. Draft landscape of COVID-19 candidate vaccines (accessed 19 Feb 2021); https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Richards, S.E. Moderna edges Pfizer in COVID-19 vaccine effectiveness—and refrigeration. National Geographic (accessed 20 Nov 2020); https://www.nationalgeographic.com/science/2020/11/moderna-edges-pfizer-coronavirus-efficacy-and-refrigeration/.
Rossey, I., Saelens, X. Vaccines against human respiratory syncytial virus in clinical trials, where are we now? Expert Rev. Vaccines 18, 1053–1067 (2019).
Mokomane, M., Kasvosve, I., de Melo, E., Pernica, J. M. & Goldfarb, D. M. The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management. Ther. Adv. Infect. Dis. 5, 29–43 (2018).
Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M. & Olesen, O. F. The status of tuberculosis vaccine development. Lancet Infect. Dis. 20, e28–37 (2020).
Basha, S., Surendran, N. & Pichichero, M. Immune responses in neonates Expert Rev. Clin. Immunol. 10, 1171–1184 (2014).
Kollmann, T. R., Kampmann B., Mazmanian S. K., Marchant A. & Levy O. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity 46, 350–363 (2017).
Aronoff, S. C., Hall, A. & Del Vecchio, M. T. The natural history of severe acute respiratory syndrome coronavirus 2-related multisystem inflammatory syndrome in children: a systematic review. J. Pediatr. Infect. Dis. Soc. 9, 746–751 (2020).
Hemati, Z. et al. Association of sleep duration with metabolic syndrome and its components in children and adolescents; a propensity score-matched analysis: the CASPIAN-V study. Diabetol. Metab. Syndr. 10, 78 (2018).
Weber, D. J., Rutala, W. A., Samsa, G. P., Santimaw, J. E. & Lemon S. M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254, 3187–3189 (1985).
Eliakim A., Swindt C., Zaldivar F., Casali P. & Cooper D. M. Reduced tetanus antibody titers in overweight children. Autoimmunity 39, 137–141 (2006).
Green, W. D. & Beck, M. A. Obesity impairs the adaptive immune response to influenza virus. Ann. Am. Thorac. Soc. 14, S406–S409 (2017).
Hernández-Garduño, E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. Obes. Res. Clin. Pract. 14, 375–379 (2020).
States National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research involving Children (1977).
Pfizer Gets FDA Approval to Enroll Kids as Young As 12 in COVID-19 Vaccine Trial: Shots. Health News: NPR (2020); https://www.npr.org/sections/health-shots/2020/10/13/923248377/will-kids-get-a-covid-19-vaccine-pfizer-to-expand-trial-to-ages-12-and-up.
Kulkarni, P. Current topics in research ethics in vaccine studies. Perspect. Clin. Res. 2013 4, 80–83 (2013).
Hodgson, S. H. et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 21, e26-e352020 (2021).
Boyle, P. We can’t defeat COVID-19 without vaccinating children. There aren’t even any kids’ clinical trials yet. AAMC (2020); https://www.aamc.org/news-insights/we-can-t-defeat-covid-19-without-vaccinating-children-there-arent-even-any-kids-clinical-trials-yet.
Geoghegan, S. O’Callaghan, K. P. & Offit, P. A. Vaccine safety: myths and misinformation. Front. Microbiol. 11, 372 (2020).
Davidson, M. Vaccination as a cause of autism-myths and controversies. Dialogues Clin. Neurosci. 19, 403–407 (2017).
Doherty, M. et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 34, 6681–6690 (2016).
Goyal, M. K. et al. Racial and ethnic differences in emergency department pain management of children with fractures. Pediatrics 145, 1–11 (2020).
Moore, J. T. et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5–18, 2020—22 States, February–June 2020. MMWR Morb. Mortal Wkly Rep. 69, 1122–1126 (2020).
Kim, L. et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19—COVID-NET, 14 States, March 1–July 25, 2020. MMWR Morb. Mortal Wkly Rep. 69, 1081–1088 (2020).
Anandappa, M. et al. Racial disparities in vaccination for seasonal influenza in early childhood. Public Health 158, 1–8 (2018).
Webb, N. S., Dowd-Arrow, B., Taylor, M. G. & Burdette, A. M. Racial/ethnic disparities in influenza vaccination coverage among US adolescents, 2010-2016. Public Health Rep. 133, 667–676 (2018).
Woinarowicz, M. & Howell, M. Comparing vaccination coverage of American Indian children with White children in North Dakota. Public Health 186, 78–82 (2020).
Santibanez, T. A. et al. Parental vaccine hesitancy and childhood influenza vaccination. Pediatrics 146, e2020007609 (2020).
Aristizabal, P. et al. Participation in pediatric oncology research protocols: racial/ethnic, language and age-based disparities. Pediatr. Blood Cancer 62, 1337–1344 (2015).
Missing from state plans to distribute the coronavirus vaccine: money to do it. The New York Times (2020); https://www.nytimes.com/2020/11/14/health/covid-vaccine-distribution-plans.html
Edwards, K. M., et al. Countering vaccine hesitancy. Pediatrics 138, e20162146 (2016).
Karafillakis, E. et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum. Vaccines Immunother. 15, 1615–1627 (2019).
Simon, G. R. et al. Medical versus nonmedical immunization exemptions for child care and school attendance. Pediatrics 138, e20162145 (2016).
Friedman, C. et al. Toward a science of learning systems: a research agenda for the high-functioning learning health system. J. Am. Med. Informatics Assoc. 22, 43–50 (2014).
Cooper, D. M. et al. Reopening schools safely: the case for collaboration, constructive disruption of pre-coronavirus 2019 expectations, and creative solutions. J. Pediatr. 223, 183–185 (2020).
Acknowledgements
The authors acknowledge NIH NCATS UCI Clinical and Translational Science Award UL1 TR001414. Support was provided in part by the Robert Wood Johnson Foundation to E.R.U.
Author information
Authors and Affiliations
Contributions
D.M.C. conceptualized and outlined the commentary. B.A., C.K.C., L.F.R., K.D.L., C.T.L., S.R.-A., W.E.S., J.T., E.R.U., and F.Z. contributed sections and paragraphs. C.L.B. and J.S. edited and reviewed the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cooper, D.M., Afghani, B., Byington, C.L. et al. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res 90, 966–970 (2021). https://doi.org/10.1038/s41390-021-01402-z
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41390-021-01402-z
This article is cited by
-
Pediatric Research and COVID-19: the changed landscape
Pediatric Research (2022)
-
A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
Bulletin of the National Research Centre (2021)
-
Children and the American Rescue Plan: countering COVID-19 vaccine hesitancy during a global pandemic
Pediatric Research (2021)
-
SARS-CoV-2 acquisition and immune pathogenesis among school-aged learners in four diverse schools
Pediatric Research (2021)
